Sajazir Injection
Product Images NDC 70709-013

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Sajazir (NDC 70709-013). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cycle Pharmaceuticals Ltd-uk, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (47e6ba7b 2204 45ec B29f F2baaf56fa65 01)

Chemical structure diagram of icatibant, the active ingredient in SAJAZIR injection. The image depicts the molecular structure with various functional groups and side chains clearly illustrated in a two-dimensional format.*

FDA Label Image

Image (47e6ba7b 2204 45ec B29f F2baaf56fa65 02)

A Kaplan-Meier curve showing the proportion of patients not achieving a 50% reduction in symptoms over time (hours) after dose, comparing Icatibant injection (solid line, N=43) versus placebo (dashed line, N=45). The graph illustrates faster symptom reduction with Icatibant compared to placebo up to 60 hours post-dose.*

FDA Label Image

Image (47e6ba7b 2204 45ec B29f F2baaf56fa65 03)

An instructional illustration showing components of a SAJAZIR prefilled injection syringe. The labeled parts include the plunger, syringe barrel, and protective cap over the syringe tip. Separate smaller diagrams show a capped needle with needle cap and seal, and an alcohol wipe packet (not included). The image details assembly components for subcutaneous injection delivery of SAJAZIR 30 mg/3 mL.*

FDA Label Image

Image (47e6ba7b 2204 45ec B29f F2baaf56fa65 04)

An instructional illustration showing hands holding and sliding open the packaging of SAJAZIR (icatibant injection) 30 mg/3 mL (10 mg/mL) intended for subcutaneous use. The diagram highlights the carton and visible injectable syringe inside, demonstrating how to pull out the product from its box.*

FDA Label Image

Image (47e6ba7b 2204 45ec B29f F2baaf56fa65 05)

An instructional illustration showing two hands preparing a medication vial and a syringe, presumably demonstrating the steps to withdraw a liquid drug dose for subcutaneous injection.*

FDA Label Image

Image (47e6ba7b 2204 45ec B29f F2baaf56fa65 06)

An instructional illustration showing how to use a syringe for subcutaneous injection. The image depicts hands holding a syringe and an injection vial, demonstrating the action of drawing medication from the vial into the syringe, likely related to SAJAZIR (Icatibant) injection.*

FDA Label Image

Image (47e6ba7b 2204 45ec B29f F2baaf56fa65 07)

An instructional diagram showing how to prepare an injection by twisting or removing a cap from a syringe. The illustration focuses on a pair of hands manipulating the syringe, emphasizing proper handling technique before subcutaneous administration.*

FDA Label Image

Image (47e6ba7b 2204 45ec B29f F2baaf56fa65 08)

An instructional medical illustration showing the recommended injection sites for subcutaneous injection on the lower abdominal area, marked by two shaded rectangular zones located on either side of the navel.*

FDA Label Image

Image (47e6ba7b 2204 45ec B29f F2baaf56fa65 09)

A black and white line drawing illustrating a hand administering a subcutaneous injection into the lower abdomen. The image depicts the anatomical area typically used for subcutaneous injection, without any text or labels.*

FDA Label Image

Image (47e6ba7b 2204 45ec B29f F2baaf56fa65 10)

An instructional illustration depicting the preparation of a subcutaneous injection using a syringe. The image shows a hand holding the syringe with the needle and another hand holding the injection site, indicating the direction to insert the needle.*

FDA Label Image

Image (47e6ba7b 2204 45ec B29f F2baaf56fa65 11)

An instructional illustration showing a hand holding a syringe, poised with the needle pointing outward. The image depicts proper grip and positioning for administering an injection, relevant to subcutaneous drug administration.*

FDA Label Image

Image (47e6ba7b 2204 45ec B29f F2baaf56fa65 12)

An instructional line drawing illustrating the subcutaneous injection technique, showing the placement of a hand and needle on the abdominal area for administering an injection.*

FDA Label Image

Image (47e6ba7b 2204 45ec B29f F2baaf56fa65 13)

An instructional diagram showing two methods of subcutaneous injection using a syringe. On the left, the syringe is inserted at a 45-degree angle, and on the right, the syringe is inserted at a 90-degree angle, both into an arm. The image includes angle indicators to clarify proper injection techniques.*

FDA Label Image

Image (47e6ba7b 2204 45ec B29f F2baaf56fa65 14)

An instructional illustration showing a hand holding a syringe injecting subcutaneously into the skin of the opposite forearm. The image demonstrates the proper technique for subcutaneous injection, relevant to the administration of SAJAZIR (Icatibant) injection 30 mg/3mL.*

FDA Label Image

Image (47e6ba7b 2204 45ec B29f F2baaf56fa65 15)

An instructional diagram showing a person administering a subcutaneous injection into the abdominal area. The illustration depicts one hand pinching the skin and the other hand holding a syringe at an angle ready for injection. This aligns with the subcutaneous injection method for SAJAZIR (Icatibant) injection.*

FDA Label Image

Image (47e6ba7b 2204 45ec B29f F2baaf56fa65 16)

An instructional illustration showing a hand injecting a subcutaneous injection into the abdominal area. A syringe is depicted with an arrow indicating the injection direction toward the skin fold.*

FDA Label Image

Image (47e6ba7b 2204 45ec B29f F2baaf56fa65 17)

An instructional diagram showing a hand holding a syringe being inserted into a sharps disposal container. The container is labeled with a biohazard symbol and the text "DO NOT RECYCLE CONTAINS SHARPS." This illustrates proper disposal of used injection needles.*

FDA Label Image

30 Of 3 (47e6ba7b 2204 45ec B29f F2baaf56fa65 18)

SAJAZIR (icatibant) injection 30 mg/3 mL (10 mg/mL) in a prefilled syringe for subcutaneous use only. The label shows manufacturing by Cipla Ltd., India, and that it is manufactured for Cycle Pharmaceuticals Ltd., Cambridge, UK. The package includes barcode and NDC 70709-013-01 information, along with Cycle Pharma logo and space for lot and expiration dates.*

FDA Label Image

30 mg Per 30 mL (47e6ba7b 2204 45ec B29f F2baaf56fa65 19)

SAJAZIR (icatibant) injection 30 mg/3 mL (10 mg/mL) label for a single 3 mL prefilled syringe. The label indicates subcutaneous use only and lists Cipla Ltd., India as the manufacturer, with Cycle Pharmaceuticals Ltd, UK as the labeler. Includes NDC 70709-013, barcode, and space for lot and expiration dates. The Cycle Pharma logo is displayed.*

FDA Label Image

30mg Per 3 Lm 1s (47e6ba7b 2204 45ec B29f F2baaf56fa65 20)

Label for SAJAZIR 30 mg/3 mL (10 mg/mL) icatibant injection, a single-dose, single-use, prefilled syringe intended for subcutaneous use only. The label includes storage instructions, inactive ingredients, manufacturing details by Cipla Ltd. India and Cycle Pharmaceuticals Ltd, UK, and a barcode. The label indicates the product is prescription-only.*

FDA Label Image

30mg Per 3 mL 3s Pack Carton (47e6ba7b 2204 45ec B29f F2baaf56fa65 21)

Packaging label for SAJAZIR (icatibant) injection 30 mg/3 mL (10 mg/mL) by Cycle Pharmaceuticals Ltd-UK. The label indicates a single-dose prefilled syringe for subcutaneous use, containing one 3 mL syringe with a 25G hypodermic needle. Manufactured by Cipla Ltd, India, and Gland Pharma Limited, India. Includes storage instructions, inactive ingredients, and barcode.*

FDA Label Image

30mg Per 3 mL 3s Pack Inner Carton (47e6ba7b 2204 45ec B29f F2baaf56fa65 22)

SAJAZIR 30 mg/3 mL (icabitant) injection carton label for subcutaneous use. The label indicates it is a single-dose, single-use prefilled syringe. The package contains three 3 mL prefilled syringes. Manufactured by Cipla Ltd., India, for Cycle Pharmaceuticals Ltd-UK. The label includes usage and storage instructions and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.